Literature DB >> 17240192

LDL particle subspecies are distinct in their capacity to mediate free cholesterol efflux via the SR-BI/Cla-1 receptor.

Morgan Tréguier1, Martine Moreau, Andrei Sposito, M John Chapman, Thierry Huby.   

Abstract

The human scavenger receptor SR-BI/Cla-1 promotes efflux of free cholesterol from cells to both high-density and low-density lipoproteins (HDL, LDL). SR-BI/Cla-1-mediated cholesterol efflux to HDL is dependent on particle size, lipid content and apolipoprotein conformation; in contrast, the capacity of LDL subspecies to accept cellular cholesterol via this receptor is indeterminate. Cholesterol efflux assays were performed with CHO cells stably transfected with Cla-1 cDNA. Expression of Cla-1 in CHO cells induced elevation in total cholesterol efflux to plasma, LDL and HDL. Such Cla-1-specific efflux was abrogated by addition of anti-Cla-1 antibody. LDL were fractionated into five subspecies either on the basis of hydrated density or size. Among LDL subfractions, small dense LDL (sdLDL) were 1.5-to 3-fold less active acceptors for Cla-1-mediated cellular cholesterol efflux. Equally, sdLDL markedly reduced Cla-1-specific cholesterol efflux to large buoyant LDL in a dose-dependent manner. Conversely, sdLDL did not influence efflux to HDL(2). These findings provide evidence that LDL particles are heterogeneous in their capacity to promote Cla-1-mediated cholesterol efflux. Relative to HDL(2), large buoyant LDL may constitute physiologically-relevant acceptors for cholesterol efflux via Cla-1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17240192     DOI: 10.1016/j.bbalip.2006.12.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.

Authors:  Petra El Khoury; Mathilde Ghislain; Elise F Villard; Wilfried Le Goff; Caroline Lascoux-Combe; Patrick Yeni; Laurence Meyer; Corinne Vigouroux; Cécile Goujard; Maryse Guerin
Journal:  J Lipid Res       Date:  2015-01-08       Impact factor: 5.922

2.  Acute consumption of walnuts and walnut components differentially affect postprandial lipemia, endothelial function, oxidative stress, and cholesterol efflux in humans with mild hypercholesterolemia.

Authors:  Claire E Berryman; Jessica A Grieger; Sheila G West; Chung-Yen O Chen; Jeffrey B Blumberg; George H Rothblat; Sandhya Sankaranarayanan; Penny M Kris-Etherton
Journal:  J Nutr       Date:  2013-04-24       Impact factor: 4.798

3.  Overexpression of the PDZ1 domain of PDZK1 blocks the activity of hepatic scavenger receptor, class B, type I by altering its abundance and cellular localization.

Authors:  Sara A Fenske; Ayce Yesilaltay; Rinku Pal; Kathleen Daniels; Attilio Rigotti; Monty Krieger; Olivier Kocher
Journal:  J Biol Chem       Date:  2008-06-10       Impact factor: 5.157

4.  Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.

Authors:  Maria Teresa Catanese; Helenia Ansuini; Rita Graziani; Thierry Huby; Martine Moreau; Jonathan K Ball; Giacomo Paonessa; Charles M Rice; Riccardo Cortese; Alessandra Vitelli; Alfredo Nicosia
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

5.  High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.

Authors:  Maria Teresa Catanese; Rita Graziani; Thomas von Hahn; Martine Moreau; Thierry Huby; Giacomo Paonessa; Claudia Santini; Alessandra Luzzago; Charles M Rice; Riccardo Cortese; Alessandra Vitelli; Alfredo Nicosia
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

6.  Association of Cholesterol Efflux Capacity With Clinical Features of Metabolic Syndrome: Relevance to Atherosclerosis.

Authors:  Julie Gall; Eric Frisdal; Randa Bittar; Wilfried Le Goff; Eric Bruckert; Philippe Lesnik; Maryse Guerin; Philippe Giral
Journal:  J Am Heart Assoc       Date:  2016-11-23       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.